Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells

Figure 1 Effects of antithrombin (AT) and various agents on the number of hepatic metastatic nodules in rats after ischemia/reperfusion (I/R). ^bP<0.01 vs sham; ^cP<0.05, ^dP<0.01 vs I/R+saline.

Figure 2 Changes in hepatic tumor necrosis factor (TNF)-α mRNA levels (A) and effects of antithrombin (AT) and various agents on TNF-α mRNA levels (B) in rats subjected to hepatic ischemia/reperfusion (I/R). ^bP<0.01 vs pre-ischemia. ^dP<0.01 vs sham and I/R+saline.

Figure 3 Changes in hepatic E-selectin mRNA levels (A) and effects of antithrombin (AT) and various agents on E-selectin mRNA levels (B) in rats subjected to hepatic ischemia/reperfusion (I/R). ^bP<0.01 vs pre-ischemia. ^dP<0.01 vs sham and I/R+saline.

Figure 4 Changes in serum concentrations of fragment E of fibrin and fibrinogen degradation products (FDP(E)) (A) and effects of antithrombin (AT), argatroban and AT+indomethacin (IM) on serum concentrations of FDP(E) (B) in rats after hepatic ischemia/reperfusion (I/R). ^bP<0.01 vs pre-ischemia. ^dP<0.01 vs sham and I/R+saline.

Figure 5 Changes in hepatic 6-keto-PGF_1α levels (A) and effects of antithrombin (AT) and AT plus indomethacin (IM) on hepatic 6-keto-PGF_1α levels (B) in rats subjected to hepatic ischemia/reperfusion (I/R). ^aP<0.05, ^bP<0.01 vs pre-ischemia. ^dP<0.01 vs sham. ^fP<0.01 vs I/R+saline and I/R+AT.

Figure 6 The number of hepatic metastatic nodules in congenital antithrombin (AT)-deficient mice. ^bP<0.01 vs AT^+/+. ^dP<0.01 vs AT^+/-